2022 Fiscal Year Final Research Report
Basic research for the novel immunotherapies targeting EMT related molecules
| Project/Area Number |
20K17573
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
Kei Ishibashi 旭川医科大学, 医学部, 客員助教 (80646076)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | EMT関連分子 |
|---|
| Outline of Final Research Achievements |
We conducted a basic study on the development of immunotherapy targeting EMT-related molecules associated with tumor invasion and metastasis, and induced CD4-positive lymphocytes targeting EMT-related molecules from healthy peripheral blood mononuclear cells. The induced lymphocytes showed antitumor effects against EMT-expressing tumor cell lines in vitro. However, in experiments using mice, induction of specific lymphocytes in mice was confirmed, but anti-tumor activity could not be confirmed. Further studies are desired in the future.
Translated with www.DeepL.com/Translator (free version)
|
| Free Research Field |
腫瘍免疫
|
| Academic Significance and Societal Importance of the Research Achievements |
癌の浸潤や転移といった，体内で進展していくために必要な能力の一つに上皮間葉移行（EMT)という癌の形質転換がしられている．その上皮間葉移行に関与する分子をEMT関連分子といい，浸潤・転移能力を持ちうる癌細胞に発現しているといわれている．本研究では，浸潤・転移能力を有するEMT関連分子を発現した癌細胞に対して特異的に抗腫瘍活性を持つリンパ球をヒトのリンパ球から誘導することができた．これによって，より悪性度の高い癌に対しての有効な新規免疫療法の開発の可能性が示唆される．
|
